Standard adjuvant chemotherapy for gastric cancer
WANG Ya-jie
Abstract：Gastric cancer is the second leading cause of death from malignant disease and most frequently discovered in advanced stages. Because curative surgery is regarded as the only option for cure, early detection of resectable gastric cancer is extremely important for good outcomes.Despite radical surgery, a significant percentage of patients undergoing curative resection do relapse, leading to poor overall survival . The recurrence is a result of occult metastatic disease in the tumor bed or distant sites, leading to an interest in the use of other forms of therapy to complement the surgical resection. Over the past 40 years, multiple randomized studies have evaluated the role of adjuvant chemotherapy in gastric cancer. Unfortunately, many of programs have used old,“suboptimal”regimens and were underpowered for survival. The recent (JAMA 2010) meta-analysis containing data from 17 randomized controlled trials demonstrated significant improvement in OS from postoperative adjuvant 5-FU-based chemotherapy when compared with surgery alone. The ACTS-GC and the CLASSIC studies evaluated the role of chemotherapy after D2 resection surgery. The two studies reported a significant benefit in DFS and OS from adjuvant chemotherapy.
Keywords：gastric canceradjuvant chemotherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 629-632,633 )